Analysis Diaceutics Plc (DXRX)
6/1/2024
Analysis of Diaceutics Plc (DXRX)
Diaceutics Plc (DXRX) is showing strong bullish momentum based on the recent price action and technical indicators.- The Relative Strength Index (RSI) is indicating overbought conditions with a value of 88.41, suggesting that the stock may be due for a pullback in the short term.
- The Moving Average Convergence Divergence (MACD) indicator is showing a positive trend with the MACD line above the signal line and a positive MACD histogram, indicating bullish momentum.
- The Moving Average (MA) indicator is also trending upwards, with the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) all showing an increasing trend.
Overall, based on the technical indicators, Diaceutics Plc (DXRX) appears to be in a strong bullish trend. However, investors should be cautious of the overbought conditions indicated by the RSI and consider potential pullbacks in the short term.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided at this time. The previous results were reported on February 27, 2025, through the Transfer Agent. Before that, on January 31, 2025, the results were released after hours. The results for October 31, 2024, were not provided at the time. On August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has a strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are both healthy, and the company shows good returns on assets and equity. The most recent quarter ended on March 31, 2024, and the fiscal year ends on September 30, 2023.
Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock price has a beta of 1.264, and the 52-week range shows a moderate change.
Valuation metrics indicate a high PEG ratio and price-to-book ratio, with the company's market capitalization and enterprise value being substantial. The price-to-sales ratio and enterprise multiples are also notable.
The stock price summary includes moving averages and the 52-week high and low prices.
Lastly, dividends and splits information shows the company's dividend dates, payout ratios, and dividend yields, as well as details on past stock splits.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:- 2020: $274,515,000,000
- 2021: $365,817,000,000
- 2022: $394,328,000,000
- 2023: $383,285,000,000
From these numbers, we can observe that the company experienced a steady increase in revenue from 2020 to 2022, reaching its peak in 2022. However, there was a slight decrease in revenue in 2023 compared to 2022. This trend indicates a period of growth followed by a slight decline in revenue for the company.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with a significant portion in cash equivalents and short-term investments.
3. Non-current assets consist mainly of investments and advances, along with machinery, furniture, and equipment.
4. Total liabilities have also been increasing, but at a slower pace compared to assets.
5. Shareholders' equity has shown a positive trend, indicating a healthy financial position.
6. The company has been investing in non-current assets, which could indicate growth and expansion plans.
7. There is a consistent level of short-term debt and accounts payable over the years.
8. The company has been managing its long-term debt and non-current liabilities effectively.
9. Retained earnings have been fluctuating, suggesting varying profitability levels.
10. Overall, the company seems to be in a stable financial position with a focus on growth and maintaining a healthy balance between assets and liabilities.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational efficiency and strategic investments.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a slight improvement from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates point towards a positive trend of increasing earnings per share for the company in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Overall, the analysts are generally optimistic about the company's future sales performance, with moderate growth expected in both the quarterly and annual sales figures.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest a positive growth trend for the company, with a slight decrease in growth rate compared to the past 5 years but still showing healthy growth prospects in the near future.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median forecast of $200. However, it's important to note that there is a wide range of forecasts, from $164 to $250. The current price of $191.57 is below both the average and median forecast, suggesting that there may be potential upside according to analysts.
MACD of DXRX
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
